Breakthroughs that
See news releases about Etira, our stellar team,
Drs. Jenkins and Stebbing join Etira Board
NewsDallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath,…
Validation of ERX-208 in Ovarian Cancer
NewsSeattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th…
ERX-315-001 SITE INITIATION VISIT @TKCC
NewsSydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…
ERX-315 CLINICAL TRIAL APPROVED BY HREC
NewsDallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled "A Phase…
Etira’s Australian partner MMIC expands
NewsMelbourne, Australia - July 10, 2024: The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities…
Where to find us
Boston Office:
75 Kneeland Ave, 14th Floor
Boston. MA. 02111
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247